Resources
28 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 3/2/2021 (updated 4/5/2024)
As state policymakers confront the substance use disorder (SUD) epidemic, they require a wide range of data – often found in disparate systems – to understand its impact and craft more effective treatment programs and interventions. This report explores best practices and sources for data gathering and describes how states can help communities access and use data to support local efforts.
Posted 3/2/2021 (updated 4/4/2024)
In light of the accelerating and rapidly evolving overdose crisis in the United States (US), new strategies are needed to address the epidemic and to efficiently engage and retain individuals in care for opioid use disorder (OUD). Moreover, there is an increasing need for novel approaches to using health data to identify gaps in the cascade of care for persons with OUD.
Posted 12/2/2020 (updated 4/3/2024)
Developed for the Puerto Rico Department of Health, this toolkit discusses how to screen pregnant women for substance use, screen infants for prenatal exposure to substances, recognize the signs of NAS, utilize validated screening tools, understand the importance of provider education, and engage pregnant women in the process of treatment and referral.
Posted 11/4/2020 (updated 4/3/2024)
The updated 2020 National Rural Health Day "Key Messages & Data Points" ePublication is full of rural-relevant data points that relate to the 3 NRHD key messages.
Posted 11/4/2020 (updated 4/3/2024)
The Council of State and Territorial Epidemiologists established the PMP Subcommittee to provide a platform for information exchange and addressing the need for a standardized metrics for opioid surveillance using PMP data. PMP group members identified a need to provide guidance for new PMP data users. Group members collaborated to write and develop a very comprehensive two-part How To Guide that provides instructions for new PMP data users.
Posted 9/15/2021 (updated 4/2/2024)
Background: Opioid overdose has become the leading cause of death among adults between 25 and 54 years old in the U.S. The purpose of this study is to explore the social and relational factors that shape the current opioid overdose epidemic.
Posted 9/15/2021 (updated 4/2/2024)
Background: Rates of fatal overdose (OD) from synthetic opioids rose nearly 60 % from 2016 to 2018. 911 Good Samaritan Laws (GSLs) are an evidenced-based strategy for preventing OD fatality. This study describes patrol officers’ knowledge of their state’s GSL, experience with OD response, and their perspectives on strategies to prevent and respond to opioid OD.
Posted 3/29/2024
A planning committee of the National Academies of Sciences, Engineering, and Medicine organized and conducted a two-day virtual public workshop that brought together data experts, program implementers and evaluators, and other key interested parties to explore data collection efforts, evidence gaps, and research needs on harm reduction for people who use drugs (PWUD).
Posted 10/12/2020 (updated 3/29/2024)
The present two-fold study “Speed Limits – Harm reduction for people who use stimulants” significantly contributes to closing the gap of knowledge about which existing harm reduction interventions are effective for people who use stimulant drugs.